Does insurance cover SPRAVATO®? What to ask before you start

Insurance is the biggest practical divider in ketamine-based treatment: one medicine in the family is routinely covered, and the rest usually are not. This guide explains why, and the exact sequence to work through before your first esketamine session.

What SPRAVATO® is approved for

SPRAVATO® (esketamine nasal spray) is FDA-approved for two uses in adults: treatment-resistant depression (as monotherapy or in conjunction with an oral antidepressant), and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior (in conjunction with an oral antidepressant) 1. Its effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated 1. Insurance coverage generally follows the label: approved use in a REMS-certified setting is the covered case.

Everything else — IV, IM, or oral ketamine for depression, anxiety, PTSD, OCD, or chronic pain — is off-label, and most plans exclude off-label psychiatric use from coverage. That is why the commonly reported IV infusion prices in our cost guide are cash prices.

The prior authorization sequence

1. Diagnosis and history. "Treatment-resistant depression" has a working definition: inadequate response to two or more adequate oral antidepressant trials. Your prescriber will document this — it is the backbone of the authorization request.
2. The REMS requirement. SPRAVATO® is dispensed only through the SPRAVATO® REMS program in certified settings, with at least two hours of post-dose monitoring 1. Your clinic must be certified; if they are not, the prescription cannot be filled for you there.
3. Prior authorization. Your clinic typically submits this, documenting diagnosis, failed trials, and the treatment plan. Decisions commonly take days to a few weeks; denials can be appealed.
4. Cost share. Even approved, you will owe a copay or coinsurance per session, twice weekly at first. Ask the clinic's billing staff for your expected per-session cost after insurance, and ask about manufacturer copay assistance if you have commercial insurance.

If you're denied

Common denial reasons: insufficient documentation of failed antidepressant trials, the clinic not being REMS-certified, or the plan classifying the use as off-label. Appeals succeed most often when the prescriber adds the trial history the plan asked for. If your plan denies SPRAVATO® entirely, the off-label IV route is the fallback — but it is self-pay, so read the cost breakdown first.

Questions to ask, in one list

• Am I covered for an approved use (TRD or MDD with acute suicidal ideation), or is my diagnosis off-label?
• Is the clinic I'm considering REMS-certified?
• What is my expected copay per session, including the monitoring window?
• What happens to coverage after the initial phase — do maintenance doses stay covered?
• Does my plan require a specific pharmacy or specialty distributor?

Our provider directory lets you filter clinics by insurance acceptance so you can shortlist before making calls — and our complete 2026 ketamine guide covers the full landscape if you're still comparing routes.

Sources

1. FDA Prescribing Information for SPRAVATO® (esketamine), revised January 2025: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf. Coverage specifics are plan-dependent; this guide describes common patterns, not benefits. Confirm details with your insurer and clinic.